NIH-funded research R03 grant

Exploring how Erythropoietin affects blood cell development in humans

Official title: Investigating the Cell Type- and Receptor-Specific Effects of Erythropoietin that Mediate Erythropoiesis and Thrombopoiesis in Primary Human Hematopoietic Progenitor Cells

Funded at University of Connecticut Sch of Med/dnt · NIH-11085827 · Data updated 2026-11-12

This study is looking at how a hormone called Erythropoietin (EPO) affects the growth of different blood cells in people, especially to help improve treatments for those with anemia, like patients with chronic kidney disease.

Quick facts

Grant typeR03 grant
Study typeNIH-funded research
Funding institutionUniversity of Connecticut Sch of Med/dnt
NIH-funded
Lab location1 site (Farmington, United States)
Project startDecember 1, 2023
Project endApril 29, 2025
Funding year2025
Award (this year)$71,762
NIH project number3R03DK135896-02S1
Project IDNIH-11085827 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are adults suffering from anemia due to chronic kidney disease.

Less likely to help

Patients who do not have chronic kidney disease or anemia may not benefit from this research.

What this research studies

This research investigates the effects of Erythropoietin (EPO), a hormone that stimulates red blood cell production, on different types of blood progenitor cells in humans. It aims to understand how EPO influences not only the formation of red blood cells but also other blood components, such as platelets, which are crucial for blood clotting. By examining the specific receptors and signaling pathways activated by EPO in these cells, the research seeks to clarify the hormone's broader role in blood cell development. This could lead to improved treatments for patients suffering from anemia, particularly those with chronic kidney disease.

Why it matters

Potential benefit: If successful, this research could lead to more effective and safer treatments for anemia in patients with chronic kidney disease.

How similar studies have gone: Previous research has shown promising results in understanding the role of EPO in blood cell development, but this specific investigation into its effects on different progenitor cells is relatively novel.

Where this research is happening

  • University of Connecticut Sch of Med/dnt
    Farmington, United States
    Active

Researchers

  • Principal investigator: Scanlon, Vanessa M. — University of Connecticut Sch of Med/dnt
  • Study coordinator: Scanlon, Vanessa M.

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.